NantHealth and NantOmics to Present Data on Tumor Mutation Burden (TMB) and PD-L1 Expression in SDH/FH Mutated Solid Tumors at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Results to be presented during the cancer prevention, hereditary genetics and epidemiology session at the ASCO 2019 Annual Meeting

NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., NH, a leading next-generation, evidence-based, personalized healthcare company, and NantOmics, LLC, the leader in molecular analyses , will present data on the association between increased TMB and increased PD-L1 expression with the presence of SDH/FH mutations in a variety of tumors, using 3,461 paired tumor/normal whole exome sequences from the NantHealth clinical cases database to look into the potential therapeutic role for inhibition of PD-1/PD-L1 pathway in these tumors during the cancer prevention, hereditary genetics and epidemiology session at the ASCO 2019 Annual Meeting, an event bringing together more than 32,000 global oncology professionals from May 31-June 4, 2019 at McCormick Place in Chicago, Illinois. NantHealth and NantOmics conducted this study with researchers from Virginia Commonwealth University's Massey Cancer Center. NantWorks will be exhibiting at booth #24080 during the event.

"We believe the data from our retrospective analysis may impact the use of immunotherapy for SDH/FH deficient tumors," said Sandeep "Bobby" Reddy, MD, Chief Medical Officer, NantHealth. "Our analysis provides actionable insight and evidence-based support to further our mission of optimizing patient outcomes and enabling value-based care, specifically in the oncology realm."

Presentation Details

Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors, Abstract #1524
WHO: NantHealth, Inc. and NantOmics, LLC
WHAT: Cancer Prevention, Hereditary Genetics and Epidemiology Session
WHEN: June 3, 1:15-4:15 PM CDT
WHERE: Hall A, McCormick Place

Presentation Summary

Succinate Dehydrogenases and Fumarate Hydratase (SDH/FH) deficient tumors are characterized by succinate/fumarate accumulation and resultant pseudohypoxia that drives malignant transformation. It has been recently shown that HIF-1a stabilization due to hypoxia can lead to upregulation of PD-1 ligand. This study explored tumor mutation burden (TMB), gene expression of PD-L1 and expression of other immune checkpoint-associated genes in a diverse cohort of human tumors harboring SDH A, B, C, D and FH mutations. Retrospective analysis was performed on 3,461 paired tumor/normal whole exome sequences (WES; ~150x coverage) from the NantHealth clinical cases database. 42 clinical cases with potentially pathogenic variants (pPV) in SDHx and FH were identified. Variant pathogenicity was assessed by multiple factors including driver gene status, variant class (e.g. Missense), PhastCons conservation score and population allele frequency. The study found an association between increased TMB and increased PD-L1 expression with the presence of SDH/FH mutations in a variety of tumors. These key parameters imply that a higher TMB may drive the evolutionary pressure to select clones with a PD-L1 high phenotype. This observation supports a potential therapeutic role for inhibition of PD-1/PD-L1 pathway in these tumors.

About NantHealth:

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payers, patients and biopharmaceutical organizations. NantHealth enables the use of cutting edge data and technology towards the goal of empowering clinical decision support and improving patient outcomes. NantHealth's comprehensive product portfolio combines the latest technology in molecular analysis (GPS Cancer^® and Liquid GPS^®), payer/provider platforms that exchange information in near-real time (NaviNet and Eviti), and connected care solutions that deliver Medical Device Interoperability (MDI). NantHealth's GPS Cancer^® molecular profiling provides comprehensive DNA & RNA tumor-normal profiling combined with pharmacogenomics analysis. Liquid GPS^® provides non-invasive testing of cfDNA and cfRNA to monitor cancer mutations and potentially select targeted therapies, chemotherapies, and immunotherapies. For more information, please visit www.nanthealth.com.

About NantOmics:

NantOmics, a member of the NantWorks ecosystem of companies, invented and developed the technologies that drive NantHealth's GPS Cancer^® platform. GPS Cancer^® provides actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing molecular variances and profiles that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances from DNA to RNA to protein to drug. Having pioneered tumor-normal DNA sequencing and introduced whole RNA transcriptomic analysis to better inform clinical treatment decisions, NantOmics has provided molecular insights for thousands of cancer patients.

NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time and correlating proteomic pathway analysis with quantitative gene expression and pharmacogenomic signatures, which guides the use of immunotherapies, chemotherapies and targeted therapies. Clinical studies for neoepitope vaccines using NantOmics' proprietary technologies and novel artificial intelligence platforms are currently underway. For more information please visit www.nantomics.com.

About VCU and VCU Health

Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 217 degree and certificate programs in the arts, sciences and humanities. Thirty-eight of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 11 schools and three colleges. The VCU Health brand represents the VCU health sciences academic programs, the VCU Massey Cancer Center and the VCU Health System, which comprises VCU Medical Center (the only academic medical center and Level I trauma center in the region), Community Memorial Hospital, Children's Hospital of Richmond at VCU, MCV Physicians and Virginia Premier Health Plan. For more, please visit www.vcu.edu and www.vcuhealth.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005490/en/